At the news
? BULLISHIMPACT 7/10 8-K filed Apr 22, 2026 at 07:00 ET
Certara agreed to sell its regulatory and medical writing business to Veristat for up to $135 million in cash, consisting of $100 million upfront and up to $35 million in earn-outs. The move sharpens focus on its core Model-Informed Drug Development (MIDD) platform and is expected to close in Q2 2026.
- Certara is selling its regulatory and medical writing business to Veristat
- Total consideration is up to $135 million: $100 million upfront cash and $35 million in contingent earn-outs
- The business generated $50 million in revenue and $17 million in adjusted EBITDA in 2025
- Transaction expected to close in Q2 2026, subject to customary conditions
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access